Diabetes: Control - Slide 19

UKPDS 10 yr Follow-Up Study-
metformin group

• Differences in A1C between intensive & standard glycemic control treatment groups were lost after one year

• Relative risk reductions at 10 yr in intensive metformin group:

• 21% for any diabetes end point (P=0.01)

• 33% myocardial infarction (P=0.005)

• 21% death from any cause (P=0.002)

N Engl J Med 2008; 359

Note:

• Differences in A1C between intensive & standard glycemic control treatment groups were lost one year after of the end of the original study.

• “Despite early loss of glycemic differences in the groups, a continued reduction in microvascular risk and emergent risk reductions for MI and death from any cause were observed during 10 years of post-trial follow up.”

• Relative risk reductions in the intensive metformin group:

  • 21% for any diabetes-related end point (P=0.01)

  • 33% myocardial infarction (P=0.005)

  • 21% death from any cause (P=0.002)

Reference

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes N Engl J Med 2008; 359
N Engl J Med 10.1056/NEJMoa0806470

Revised November 2008